Segal Lloyd Mitchell bought AKTS
January 12, 2026 · Form 4 insider transaction
Segal Lloyd Mitchell bought 19,631 shares of Aktis Oncology, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
19,631
Price
N/A
Total value
N/A
InsiderSegal Lloyd Mitchell
RoleDirector
CompanyAktis Oncology, Inc. (AKTS)
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateJanuary 12, 2026
Filing dateJanuary 12, 2026
Shares owned after19,631
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration.; Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.